Novavax (NVAX) Misses Q4 EPS, Revenues; Provides Vaccine Updates

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/2/2026

1. AMZN
2. INTC
3. RDDT
4. COIN
5. PINS
6. FSLR
7. DASH
8. SYK
9. ALNY
10. SBUX

Go back to Novavax (NVAX) Misses Q4 EPS, Revenues; Provides Vaccine Updates

Novavax Reports Fourth Quarter and Full Year 2020 Financial Results and Operational Highlights

March 1, 2021 4:02 PM EST

96% vaccine efficacy against original COVID-19 in UK Phase 3 trialVaccine cross-protection demonstrated against both variants circulating in the UK and South AfricaFull enrollment (~30,000 participants) in PREVENT-19 Phase 3 trialAgreements for ~300 million doses to dateAdditional 1.1 billion doses to be supplied to the COVAX Facility (jointly with Serum Institute of India)Clinical trial of variant strain vaccines as standalone and bivalent candidates expected mid-2021Company to host conference call today at 4:30 p.m. ET

GAITHERSBURG, Md., March 01, 2021 (GLOBE NEWSWIRE) -- Novavax, Inc.... More